Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease

Clinical Science

Volumn 131, Issue 12, 2017, Pages 1301-1315

  Dongiovanni, Paola ^a   Meroni, Marica ^b   Baselli, Guido Alessandro ^a   Bassani, Giulia Alessandra ^a   Rametta, Raffaela ^a   Pietrelli, Alessandro ^a,c   Maggioni, Marco ^a   Facciotti, Federica ^d   Trunzo, Valentina ^a   Badiali, Sara ^a   Fargion, Silvia ^a,b   Gatti, Stefano ^a   Valenti, Luca ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Istituto Nazionale di Genetica Molecolare   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; CHOLINE; FATTY ACID; FRUCTOSE; INSULIN RECEPTOR; LYSYL OXIDASE LIKE 2; METHIONINE; PROTEIN LYSINE 6 OXIDASE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; FOXO1 PROTEIN, MOUSE; LOXL2 PROTEIN, HUMAN; LOXL2 PROTEIN, MOUSE; OXIDOREDUCTASE;

ADIPOGENESIS; ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CELL ADHESION; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CONDITIONED MEDIUM; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; ENZYME INDUCTION; ENZYME STABILITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FAT CONTENT; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; GENE SILENCING; HAPLOINSUFFICIENCY; HEPATIC STELLATE CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; LIPOGENESIS; LIPOTOXICITY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MOLECULAR PATHOLOGY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COMPLICATION; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; LIVER; LIVER CIRRHOSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHENOTYPE; VITAMIN DEFICIENCY;

AMINO ACID OXIDOREDUCTASES; ANIMALS; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; CHOLINE DEFICIENCY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; EXTRACELLULAR MATRIX; FORKHEAD BOX PROTEIN O1; GENETIC PREDISPOSITION TO DISEASE; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; METHIONINE; MICE, INBRED C57BL; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 85020291626     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20170175     Document Type: Article

References (46)

1. Rinella, M.E. (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313, 2263-2273
2. Petta, S., Valenti, L., Bugianesi, E., Targher, G., Bellentani, S., Bonino, F. et al. (2016) A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Dig. Liver Dis. 48, 333-342
3. Petaja, E.M. and Yki-Jarvinen, H. (2016) Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-a systematic review. Int. J. Mol. Sci. 17, 633
4. Nascimbeni, F., Pais, R., Bellentani, S., Day, C.P., Ratziu, V., Loria, P. et al. (2013) From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 59, 859-871
5. Dongiovanni, P., Rametta, R., Meroni, M. and Valenti, L. (2016) The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development-a potential therapeutic target? Expert Rev. Gastroenterol. Hepatol. 10, 229-242
6. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P. et al. (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389-397.e10
7. McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P. and Anstee, Q.M. (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148-1155
8. Pelusi, S., Petta, S., Rosso, C., Borroni, V., Fracanzani, A.L., Dongiovanni, P. et al. (2016) Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS ONE 11, e0163069
9. Dongiovanni, P., Valenti, L., Rametta, R., Daly, A.K., Nobili, V., Mozzi, E. et al. (2010) Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59, 267-273
10. Ratziu, V. (2013) Pharmacological agents for NASH. Nat. Rev. Gastroenterol. Hepatol. 10, 676-685
11. Musso, G., Cassader, M., Paschetta, E. and Gambino, R. (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern. Med. 177, 633-640
12. Accili, D., Drago, J., Lee, E.J., Johnson, M.D., Cool, M.H., Salvatore, P. et al. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12, 106-109
13. Nakae, J., Biggs, III, W.H., Kitamura, T., Cavenee, W.K., Wright, C.V., Arden, K.C. and Accili, D. (2002) Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32, 245-253
14. Okamoto, H. and Accili, D. (2003) In vivo mutagenesis of the insulin receptor. J. Biol. Chem. 278, 28359-28362
15. Rametta, R., Mozzi, E., Dongiovanni, P., Motta, B.M., Milano, M., Roviaro, G. et al. (2013) Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int. J. Obes. (Lond.) 37, 986-992
16. Cook, J.R., Langlet, F., Kido, Y. and Accili, D. (2015) Pathogenesis of selective insulin resistance in isolated hepatocytes. J. Biol. Chem. 290, 13972-13980
17. Anstee, Q.M. and Goldin, R.D. (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1-16
18. Rinella, M.E., Elias, M.S., Smolak, R.R., Fu, T., Borensztajn, J. and Green, R.M. (2008) Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49, 1068-1076
19. Dongiovanni, P., Romeo, S. and Valenti, L. (2015) Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res. Int. 2015, 460190
20. Mancina, R.M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R. et al. (2016) The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219-1230.e6
21. Lee, U.E. and Friedman, S.L. (2011) Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 25, 195-206
22. Vadasz, Z., Kessler, O., Akiri, G., Gengrinovitch, S., Kagan, H.M., Baruch, Y. et al. (2005) Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J. Hepatol. 43, 499-507
23. Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H.M., Oyasu, M. et al. (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009-1017
24. Okamoto, H., Nakae, J., Kitamura, T., Park, B.C., Dragatsis, I. and Accili, D. (2004) Transgenic rescue of insulin receptor-deficient mice. J. Clin. Invest. 114, 214-223
25. Accili, D. and Arden, K.C. (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426
26. Italian Association for the Study of the Liver (AISF), Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F. et al. (2017) AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig. Liver Dis. 49, 471-483
27. Valenti, L., Bugianesi, E., Pajvani, U. and Targher, G. (2016) Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 36, 1563-1579
28. Zhang, W., Bu, S.Y., Mashek, M.T., O-Sullivan, I., Sibai, Z., Khan, S.A. et al. (2016) Integrated regulation of hepatic lipid and glucose metabolism by adipose triacylglycerol lipase and FoxO proteins. Cell Rep. 15, 349-359
29. Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D. and Brenner, D.A. (2007) The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 132, 1434-1446
30. Dejean, A.S., Hedrick, S.M. and Kerdiles, Y.M. (2011) Highly specialized role of Forkhead box O transcription factors in the immune system. Antioxid. Redox Signal. 14, 663-674
31. Ma, C., Kesarwala, A.H., Eggert, T., Medina-Echeverz, J., Kleiner, D.E., Jin, P. et al. (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253-257
32. Marra, F. and Bertolani, C. (2009) Adipokines in liver diseases. Hepatology 50, 957-969
33. Trautwein, C., Friedman, S.L., Schuppan, D. and Pinzani, M. (2015) Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15-S24
34. Argo, C.K., Northup, P.G., Al-Osaimi, A.M. and Caldwell, S.H. (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371-379
35. Aravinthan, A., Challis, B., Shannon, N., Hoare, M., Heaney, J. and Alexander, G.J. (2015) Selective insulin resistance in hepatocyte senescence. Exp. Cell Res. 331, 38-45
36. Naimi, M., Gautier, N., Chaussade, C., Valverde, A.M., Accili, D. and Van Obberghen, E. (2007) Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. Endocrinology 148, 2424-2434
37. Garcia-Monzon, C., Lo Iacono, O., Mayoral, R., Gonzalez-Rodriguez, A., Miquilena-Colina, M.E., Lozano-Rodriguez, T. et al. (2011) Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J. Hepatol. 54, 142-152
38. Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E. et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48, 792-798
39. Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A. et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37, 1286-1292
40. Maximos, M., Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Biernacki, D. et al. (2015) The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61, 153-160
41. Meissner, E.G., McLaughlin, M., Matthews, L., Gharib, A.M., Wood, B.J., Levy, E. et al. (2016) Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 36, 1783-1792
42. Ikenaga, N., Peng, Z.W., Vaid, K.A., Liu, S.B., Yoshida, S., Sverdlov, D.Y. et al. (2017) Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut, doi:10.1136/gutjnl-2016-312473
43. Magdaleno, F. and Trebicka, J. (2017) Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression. Gut, doi:10.1136/gutjnl-2016-313621
44. Witek, R.P., Yang, L., Liu, R., Jung, Y., Omenetti, A., Syn, W.K. et al. (2009) Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 136, 320-330.e2
45. Kornek, M., Popov, Y., Libermann, T.A., Afdhal, N.H. and Schuppan, D. (2011) Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 53, 230-242
46. Akazawa, Y. and Nakao, K. (2016) Lipotoxicity pathways intersect in hepatocytes: endoplasmic reticulum stress, c-Jun N-terminal kinase-1, and death receptors. Hepatol. Res. 46, 977-984